Citius Pharmaceuticals, Inc.
-$31.69M- Market cap
- $16.13M
- Debt
- +-$6.11M
- Cash
- −$41.71M
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: CTXR stock price at premium vs ADNT $0.59 current versus $0.00 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ADNT's multiple
Implied fair value · at CTXR's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTXR FY 2022 (ended Sep 30, 2022) · ADNT FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 39% equity / 61% debt
ADNT carries the larger enterprise value at $3.93B against -$31.69M; CTXR trades on the lower EV / EBITDA multiple (0.96x vs 24.11x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Adient plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.06x
1.35x
Net debt / EBITDA
Leverage against operating earnings
1.45x
—
Cash and equivalents
Liquid reserves on the balance sheet
$41.71M
—
Total debt
Interest-bearing obligations outstanding
-$6.11M
$2.39B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
CTXR vs ZOM
Aquestive Therapeutics, Inc.
CTXR vs AQST
ACADIA PHARMACEUTICALS INC
CTXR vs ACAD
AMGEN INC
CTXR vs AMGN
GILEAD SCIENCES, INC.
CTXR vs GILD
AbbVie Inc.
CTXR vs ABBV
AMERICAN AXLE & MANUFACTURING HOLDINGS INC
CTXR vs AXL
VISTEON CORP
CTXR vs VC
DANA INC
CTXR vs DAN
BORGWARNER INC
CTXR vs BWA
FOX FACTORY HOLDING CORP
CTXR vs FOXF
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.